Yong Gil Na

Yong Gil Na

Auto-generated profile, based on publicly available information

Yong Gil Na

Department of Urology, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, Korea

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Autonomic Neuroscience
Verified
Journal Article
Closed access
AKAdam P. Klausner
Adam P. Klausner
TSTomi Streng
Tomi Streng
YNYong-Gil Na
Yong-Gil Na
JRJerry Raju
Jerry Raju
TBTimothy W. Batts
Timothy W. Batts
WSWilliam D. Steers
William D. Steers

2 January 2015 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JSJu Hyun Shin
Ju Hyun Shin
SCSunga Choi
Sunga Choi
YLYu Ran Lee
Yu Ran Lee
MPMyoung Soo Park
Myoung Soo Park
YNYong Gil Na
Yong Gil Na
Byeong Hwa JeonByeong Hwa Jeon
Byeong Hwa Jeon
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer. Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1. Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548 ± 0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547 ± 0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence. Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.

1 April 2018 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
HCHyun-Sop Choe
Hyun-Sop Choe
SLSeung-Ju Lee
Seung-Ju Lee
YCYong-Hyun Cho
Yong-Hyun Cho
MÇMete Çek
Mete Çek
ZTZafer Tandoğdu
Zafer Tandoğdu
ZXZhang Xiangbo
Zhang Xiangbo
To assess Asian data from Global Prevalence Study on Infections in Urology (GPIU study) which has been performed more than 10 years. Seventeen Asian countries participated in the GPIU study between 2004 and 2013. Data for these countries were collected from the web-based GPIU database. The point prevalence of urinary tract infections (UTI) and antimicrobial susceptibility of representative pathogens were analysed for Asian geographic regions. A total of 6706 patients (5271 male, 1435 female) were assessed during the study period, and 659 patients were diagnosed with a UTI (9.8%). Of these UTI patients, 436 were male and 223 were female. Mean patient age was 54.9 ± 19.3 years. Pyelonephritis and cystitis were the most common clinical diagnoses, representing 30.7% and 29.9% of patients, respectively. Escherichia coli was the most frequently identified uropathogen (38.7%). For the patients with urinary tract infection, cephalosporins were the most frequently used antibiotics (34.4%), followed by fluoroquinolones (24.1%), aminoglycosides (16.8%). Fluoroquinolone resistance was relatively high (ciprofloxacin 54.9%, levofloxacin 39.0%), and cephalosporin resistance 42% (42.5-49.4%). Of the antibiotics evaluated, uropathogens had maintained the highest level of susceptibility to amikacin and imipenem (24.9% and 11.3% resistance rates, respectively). Uropathogens in many Asian countries had high resistance to broad-spectrum antibiotics. Knowledge of regional and local resistance data and prudent use of antibiotics are important for proper management of UTI in Asian countries.

1 June 2010 in European Urology
Verified
Journal Article
Closed access
KLKyu-Sung Lee
Kyu-Sung Lee
YLYoung-Suk Lee
Young-Suk Lee
JSJu Tae Seo
Ju Tae Seo
YNYong Gil Na
Yong Gil Na
MCMyung-Soo Choo
Myung-Soo Choo
JLJeong Zoo Lee
Jeong Zoo Lee

1 November 2003 in Journal of Urology
Verified
Journal Article
Closed access
KLKyu-Sung Lee
Kyu-Sung Lee
YNYong-Gil NA
Yong-Gil NA
TDTRAVIS DEAN-McKINNEY
TRAVIS DEAN-McKINNEY
AKAdam P. Klausner
Adam P. Klausner
JTJeremy B. Tuttle
Jeremy B. Tuttle
WSWilliam D. Steers
William D. Steers
Purpose: Because serotonin (5-HT) in the central nervous system may inhibit bladder activity, we postulated that depression associated with altered 5-HT function might be associated with ov...

1 January 2016 in Disease Markers
Verified
Journal Article
Open access
PDF file
SCSunga Choi
Sunga Choi
JSJu Hyun Shin
Ju Hyun Shin
YLYu Ran Lee
Yu Ran Lee
HJHee Kyoung Joo
Hee Kyoung Joo
KSKi Hak Song
Ki Hak Song
Byeong Hwa JeonByeong Hwa Jeon
Byeong Hwa Jeon
Bladder cancer (BCa) is one of the most common urothelial cancers with still noticeable incidence rate. Early detection of BCa is highly correlated with successful therapeutic outcomes. We previously showed that apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) was expressed at an increased level in the serum of BCa patients when compared to the level in healthy controls. In this study, we investigated whether urinary APE1/Ref-1 was also elevated in patients with BCa. In this case-control study, voided urine was collected from 277 subjects including 169 BCa patients and 108 non-BCa controls. Urinary APE1/Ref-1 level was assessed by enzyme-linked immunosorbent assay (ELISA). APE1/Ref-1 levels were significantly elevated in BCa patients relative to levels in non-BCa controls and were correlated with tumor grade and stage. Urinary APE1/Ref-1 levels were also higher in patients with recurrence history of BCa. The receiver operating characteristics (ROC) curve of APE1/Ref-1 showed an area under the curve of 0.83, indicating the reliability and validity of this biomarker. The optimal combination of sensitivity and specificity was determined to be 82% and 80% at a cut-off value of 0.376 ng/100 μL for detection of APE1/Ref-1 in urine. In conclusion, urinary APE1/Ref-1 levels measured from noninvasively obtained body fluids would be clinically applicable for diagnosis of BCa.